

Erik Stomrud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2797738/publications.pdf>

Version: 2024-02-01

68
papers

5,796
citations

136885

32
h-index

149623

56
g-index

75
all docs

75
docs citations

75
times ranked

5560
citing authors

#	ARTICLE	IF	CITATIONS
1	Discriminative Accuracy of Plasma Phospho-tau ₂₁₇ for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 772.	3.8	640
2	Earliest accumulation of β -amyloid occurs within the default-mode network and concurrently affects brain connectivity. <i>Nature Communications</i> , 2017, 8, 1214.	5.8	596
3	CSF biomarkers of Alzheimer's disease concord with amyloid β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. <i>Alzheimer's and Dementia</i> , 2018, 14, 1470-1481.	0.4	468
4	Plasma tau in Alzheimer disease. <i>Neurology</i> , 2016, 87, 1827-1835.	1.5	371
5	$\text{CSF } A\beta_{42}/A\beta_{40}$ and $A\beta_{42}/A\beta_{38}$ ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 154-165.	1.7	329
6	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β -Amyloid Status. <i>JAMA Neurology</i> , 2019, 76, 1060.	4.5	282
7	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. <i>Nature Medicine</i> , 2021, 27, 1034-1042.	15.2	236
8	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. <i>Neurology</i> , 2018, 91, e867-e877.	1.5	207
9	$A\beta$ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. <i>Science Advances</i> , 2020, 6, eaaz2387.	4.7	202
10	Associations of Plasma Phospho-Tau ₂₁₇ Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 149.	4.5	176
11	Longitudinal plasma p-tau ₂₁₇ is increased in early stages of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3234-3241.	3.7	150
12	Staging β -Amyloid Pathology With Amyloid Positron Emission Tomography. <i>JAMA Neurology</i> , 2019, 76, 1319.	4.5	149
13	Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 118-124.	0.7	148
14	Untangling the association of amyloid- β and tau with synaptic and axonal loss in Alzheimer's disease. <i>Brain</i> , 2021, 144, 310-324.	3.7	123
15	Apathy and anxiety are early markers of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 85, 74-82.	1.5	103
16	Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults. <i>Archives of Neurology</i> , 2010, 67, 217-23.	4.9	99
17	Determining clinically meaningful decline in preclinical Alzheimer disease. <i>Neurology</i> , 2019, 93, e322-e333.	1.5	96
18	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. <i>Nature Aging</i> , 2021, 1, 114-123.	5.3	94

#	ARTICLE	IF	CITATIONS
19	Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. <i>EMBO Molecular Medicine</i> , 2021, 13, e14022.	3.3	90
20	The implications of different approaches to define AT(N) in Alzheimer disease. <i>Neurology</i> , 2020, 94, e2233-e2244.	1.5	80
21	Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease. <i>PLoS ONE</i> , 2009, 4, e6294.	1.1	79
22	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 76.	2.4	78
23	Increased midlife triglycerides predict brain β -amyloid and tau pathology 20 years later. <i>Neurology</i> , 2018, 90, e73-e81.	1.5	76
24	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A β 42/A β 40 and p-tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 283-293.	0.4	72
25	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 149.	4.5	66
26	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. <i>Brain</i> , 2021, 144, 2826-2836.	3.7	65
27	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. <i>Neurology</i> , 2021, 97, e1681-e1694.	1.5	60
28	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021, 13, e14398.	3.3	58
29	Greater tau load and reduced cortical thickness in APOE ϵ 4-negative Alzheimer's disease: a cohort study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 77.	3.0	56
30	Accurate risk estimation of β -amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. <i>Alzheimer's and Dementia</i> , 2019, 15, 194-204.	0.4	49
31	Increased amyloidogenic APP processing in APOE ϵ 4-negative individuals with cerebral β -amyloidosis. <i>Nature Communications</i> , 2016, 7, 10918.	5.8	48
32	Towards a unified protocol for handling of CSF before β -amyloid measurements. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 63.	3.0	38
33	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 95, 143-153.	1.5	34
34	Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness. <i>Cerebrovascular Diseases Extra</i> , 2015, 5, 41-51.	0.5	33
35	Altered structural network organization in cognitively normal individuals with amyloid pathology. <i>Neurobiology of Aging</i> , 2018, 64, 15-24.	1.5	30
36	Brain myoinositol as a potential marker of amyloid-related pathology. <i>Neurology</i> , 2019, 92, e395-e405.	1.5	30

#	ARTICLE	IF	CITATIONS
37	Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. <i>Scientific Reports</i> , 2021, 11, 1965.	1.6	28
38	Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 403-411.	1.2	26
39	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ϵ 4, sex and age. <i>Progress in Neurobiology</i> , 2021, 198, 101904.	2.8	25
40	Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. <i>Alzheimer's and Dementia</i> , 2023, 19, 797-806.	0.4	24
41	Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer's Disease Pathology and Cognitive Decline. <i>Biological Psychiatry</i> , 2022, 92, 34-43.	0.7	21
42	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. <i>Hippocampus</i> , 2017, 27, 653-667.	0.9	20
43	Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12137.	1.2	20
44	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE ϵ 4 carriers. <i>Scientific Reports</i> , 2020, 10, 8233.	1.6	17
45	Association of CSF $A\beta_{38}$ Levels With Risk of Alzheimer Disease-Related Decline. <i>Neurology</i> , 2022, 98, .	1.5	16
46	Effects of APOE ϵ 4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 71, 81-90.	1.5	15
47	Derivation and utility of an $A\beta$ -PET pathology accumulation index to estimate $A\beta$ load. <i>Neurology</i> , 2020, 95, e2834-e2844.	1.5	14
48	The protective gene dose effect of the APOE ϵ 2 allele on gray matter volume in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2022, 18, 1383-1395.	0.4	13
49	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 683-691.	1.7	8
50	Components of gait in people with and without mild cognitive impairment. <i>Gait and Posture</i> , 2022, 93, 83-89.	0.6	7
51	Mild behavioral impairment is predictive of tau deposition in the earliest stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042595.	0.4	6
52	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	6
53	Psychometric testing of a Swedish version of the Apathy Evaluation Scale. <i>Nordic Journal of Psychiatry</i> , 2017, 71, 477-484.	0.7	5
54	Astrocytic function is associated with both amyloid- β and tau pathology in non-demented APOE ϵ 4 carriers. <i>Brain Communications</i> , 2022, 4, .	1.5	4

#	ARTICLE	IF	CITATIONS
55	Phospho τ 217 and phospho τ 181 in plasma and CSF as biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e037520.	0.4	2
56	Prediction of future Alzheimer's disease dementia using plasma phospho τ combined with other accessible measures. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
57	Associations between longitudinal neuropsychiatric symptoms and biomarkers of beta τ amyloid, tau, neurodegeneration, and cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
58	DT τ 1 τ 04: DIAGNOSTIC PERFORMANCE OF [¹⁸ F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDER τ 2 STUDY. <i>Alzheimer's and Dementia</i> , 2019, 15, P1485.	0.4	0
59	A cost τ consequence analysis of early detection of AD in the MOPEAD project τ A project within the EU research agenda IML τ 2. <i>Alzheimer's and Dementia</i> , 2020, 16, e042774.	0.4	0
60	Improved performance of Elecsys CSF Abeta measurement achieved using the simple, unified routine τ use protocol for CSF collection. <i>Alzheimer's and Dementia</i> , 2020, 16, e047394.	0.4	0
61	Analytical characteristics of the updated elecsys Abeta42 Gen 2 assay, including comparisons with the Gen 1 assay. <i>Alzheimer's and Dementia</i> , 2020, 16, e047517.	0.4	0
62	Unravelling drivers of age τ and beta τ amyloid τ related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
63	Biomarker driven enrichment strategies for tau pathology in AD clinical trials. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
64	Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
65	Lower cognitive resilience against brain atrophy in cognitively unimpaired elderly is partly explained by Alzheimer's disease pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
66	Amyloid τ 2 accumulation is independently related to executive function in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
67	The association between diet in mid τ life and dementia incidence over a 20 τ year period. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
68	Potential drivers of age τ and beta τ amyloid τ related neurodegeneration in early and late Alzheimer's Disease regions in cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0